Indication | – Newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. – Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. – Adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. |
Status | FDA NDA final approval |
Product Advantages | – Phyrago® (Dasatinib) is an oral kinase inhibitor used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It can be used concomitantly with certain acid-reducing agents, such as proton pump inhibitors (PPIs) and H2 blockers. – Exclusivity: 3 years |
Market Size | According to information published in the original patented pharmaceutical company’s 2023 annual report, the global market sales of original drugs in 2023 will be US$1.93 billion (US$1.446 billion in the U.S. market and US$484 million in markets outside the U.S.). |